People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,555.50GBp
24 Dec 2014
Price Change (% chg)

39.00p (+0.86%)
Prev Close
4,516.50p
Open
4,542.00p
Day's High
4,573.00p
Day's Low
4,526.00p
Volume
403,816
Avg. Vol
2,570,353
52-wk High
4,946.41p
52-wk Low
3,367.07p

Search Stocks

Morrison, Briggs 

Brief Biography

Dr. Briggs Morrison is the Executive Vice President - Global Medicines Development of AstraZeneca PLC., since January 2013 and leads the global late-stage development organisation for both small molecules and biologics. He joined AstraZeneca in 2012 from Pfizer, where he was Head of Medical Excellence, overseeing development, medical affairs, safety and regulatory affairs for Pfizer’s human health businesses. Briggs has a track record of developing novel medicines in roles at both Pfizer and Merck. Briggs has a biology degree from Georgetown University and a medical doctorate from the University of Connecticut. Briggs has also undertaken an internship and residency in internal medicine at the Massachusetts General Hospital, a fellowship in medical oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in genetics at Harvard Medical School.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

540,000

Pascal Soriot

3,344,000

Marc Dunoyer

296,000

Ruud Dobber

--

Caroline Hempstead

--

Paul Hudson

--
As Of 30 Dec 2013
Search Stocks